Teicoplanin Derivatives Impact on West Nile Virus Pathogenesis †
by
Henrietta Papp
1,2,*, 
Ilona Bereczki
3, 
Pál Herczegh
3,
Mónika Madai
1,
Gábor Kemenesi
1,
Eszter Boglárka Lőrincz
3,4,
Anikó Borbás
3 and
Ferenc Jakab
1 1
National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, 7624 Pécs, Hungary
2
Doctoral School of Biology and Sportbiology, University of Pécs, 7624 Pécs, Hungary
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
4
Doctoral School of Pharmaceutical Sciences, University of Debrecen, 4032 Debrecen, Hungary
*
Author to whom correspondence should be addressed.
†
Presented at Viruses 2020—Novel Concepts in Virology, Barcelona, Spain, 5–7 February 2020.
Proceedings 2020, 50(1), 126; https://doi.org/10.3390/proceedings2020050126
Published: 8 July 2020
(This article belongs to the Proceedings of Viruses 2020—Novel Concepts in Virology)
Abstract
:West Nile virus (WNV) is an emerging arbovirus that causes infections worldwide. Clinical manifestations of the infection vary from asymptomatic to fatal illness when it reaches the central nervous system. To date, vaccine and specific antiviral treatments are not available. Teicoplanin is already used to treat Gram-positive bacterial infections. Furthermore, it has been reported to block the entry of pseudotyped Ebola, Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. Moreover, teicoplanin derivatives showed anti-influenza virus, anti-human immunodeficiency virus, anti-hepatitis C virus, and anti-dengue virus activity. In total, 12 teicoplanin derivatives have been tested against our West Nile virus isolate. Vero E6 cells were simultaneously treated with 50 µM of teicoplanin derivatives and infected with WNV at the same time. Virus-induced cytopathic effect and cytotoxicity were examined 4 days post-infection. One compound completely blocked virus pathogenesis, while five compounds reduced the viral titer. Further studies will be conducted to unravel the mode of action of these promising derivatives.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Papp, H.; Bereczki, I.; Herczegh, P.; Madai, M.; Kemenesi, G.; Lőrincz, E.B.; Borbás, A.; Jakab, F. Teicoplanin Derivatives Impact on West Nile Virus Pathogenesis. Proceedings 2020, 50, 126. https://doi.org/10.3390/proceedings2020050126
AMA Style
Papp H, Bereczki I, Herczegh P, Madai M, Kemenesi G, Lőrincz EB, Borbás A, Jakab F. Teicoplanin Derivatives Impact on West Nile Virus Pathogenesis. Proceedings. 2020; 50(1):126. https://doi.org/10.3390/proceedings2020050126
Chicago/Turabian StylePapp, Henrietta, Ilona Bereczki, Pál Herczegh, Mónika Madai, Gábor Kemenesi, Eszter Boglárka Lőrincz, Anikó Borbás, and Ferenc Jakab. 2020. "Teicoplanin Derivatives Impact on West Nile Virus Pathogenesis" Proceedings 50, no. 1: 126. https://doi.org/10.3390/proceedings2020050126
